Clinical Trials Logo

Clinical Trial Summary

To observe and evaluate the efficacy and safety of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC and the relevance with Immune Receptor Repertoire


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04897386
Study type Interventional
Source Wuhan Union Hospital, China
Contact Xiaorong Dong, PhD
Phone 027-85872859
Email xiaorongdong@hust.edu.cn
Status Not yet recruiting
Phase Phase 2
Start date June 1, 2021
Completion date December 1, 2024